BIBLIOGRAFIA UFFICIALE
- 1. **Bischoff. 2023.** “ESPEN guideline on Clinical Nutrition in Inflammatory Bowel Disease”. Clinical Nutrition.
- 2. **Bischoff.** “Linea guida pratica ESPEN: Nutrizione Clinica nella malattia infiammatoria cronica intestinale (MICI)”.
- 3. **Magavi. 2022.** “Incorporating Nutrition-Based Strategies into IBD Treatment”. Current Gastroenterology Reports, 20 ottobre.
- 4. **Chouraki. 2011.** “The changing pattern of Crohn’s disease incidence in northern France: a continuing increase in the 10- to 19-year-old age bracket (1988-2007)”. Alimentary Pharmacology & Therapeutics, 33, n. 10 (16 marzo): 1133–42.
- 5. **AMICI Italia. s.d.** “La Malattia di Crohn”.
- 6. **Singh. 2022.** “Evaluation of Nutritional Characteristics Reveals Similar Prevalence of Malnutrition in Patients with Ulcerative Colitis and Crohn’s Disease”. Digestive Diseases and Sciences, 5 settembre.
- 7. **ESPEN FACT SHEETS. s.d.** “DISEASE RELATED MALNUTRITION (DRM) A neglected threat for every patient, nutritional care matters”.
- 8. **Dhaliwal. 2021.** “Sarcopenia in Inflammatory Bowel Disease: A Narrative Overview”. Nutrients, 13, n. 2 (17 febbraio): 656.
- 9. **Burisch. 2018.** “Natural disease course of Crohn’s disease during the first 5 years after diagnosis in a European population-based inception cohort: an Epi-IBD study”. Gut, 68, n. 3 (23 gennaio): 423–33.
- 10. **Ministero della Salute. 2025.** “LINEE GUIDA SUGLI ALIMENTI A FINI MEDICI SPECIALI (AFMS). Revisione del 15 luglio 2025”.
- 11. **SINPE, SIGENP. s.d.** “Il capitolato per la gara di appalto della nutrizione enterale”.
- 12. **Rinninella. 2023.** “Botanicals in human nutrition: focus on bioactive food-derived compounds on gut microbiota in gastrointestinal inflammatory diseases”. Nutrimentum et Curae, n. 02, e134.
- 13. **Loy. 2024.** “Dietary Fiber in Inflammatory Bowel Disease: Are We Ready to Change the Paradigm?”. Nutrients, 16, n. 8 (10 aprile): 1108.
- 14. **Feldheiser. 2015.** “Enhanced Recovery After Surgery (ERAS) for gastrointestinal surgery, part 2: consensus statement for anaesthesia practice”. Acta Anaesthesiologica Scandinavica, 60, n. 3 (30 ottobre): 289–334.
- 15. **Hoshimoto. 2002.** “Caprylic acid and medium-chain triglycerides inhibit IL-8 gene transcription in Caco-2 cells: comparison with the potent histone deacetylase inhibitor trichostatin A”. British Journal of Pharmacology, 136, n. 2 (maggio): 280–86.
- 16. **Hashash. 2024.** “AGA Clinical Practice Update on Diet and Nutritional Therapies in Patients With Inflammatory Bowel Disease: Expert Review”. Gastroenterology, gennaio.
- 17. **Massironi. 2023.** “Inflammation and malnutrition in inflammatory bowel disease”. Lancet Gastroenterology & Hepatology, marzo.
- 18. **Di Stefano. 2024.** “T.11.1: MICRONUTRIENT NUTRITIONAL DEFICIENCIES IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE IN REMISSION FOLLOWING A LONG-TERM BIOLOGIC TREATMENT”. Digestive and Liver Disease, 56 (aprile): S276.
- 19. **ESPEN FACT SHEETS. s.d.** “GLIM criteria for the diagnosis of malnutrition. A consensus report from the global clinical nutrition community”.
- 20. **Regione Lombardia. 2024.** “Allegato A. Deliberazione XII / 1812. Approvato il 29 gennaio 2024”.
- 21. **Pennings. 2011.** “Whey protein stimulates postprandial muscle protein accretion more effectively than do casein and casein hydrolysate in older men”. American Journal of Clinical Nutrition, 93, n. 5 (2 marzo): 997–1005.
- 22. **AMICI Italia. s.d.** “La Colite Ulcerosa”.
- 23. **Caterina Fazion. (2024. 2024.** “Malattie croniche intestinali: in metà dei casi sintomi fuori controllo”.
- 24. **Panorama della Sanità. 2022.** “Malattia di Crohn e Colite Ulcerosa, nel 2030 si stima il raddoppio dei pazienti”. 20 maggio 2022.
- 25. **Ministero della Salute. s.d.** “Conferenza per la Giornata mondiale delle malattie croniche intestinali”.
- 26. **Cárdenas. 2022.** “Nutritional care is a human right: Translating principles to clinical practice”. Nutrition in Clinical Practice, 23 maggio.
- 27. **Regione Lombardia. 2024.** “ATTIVAZIONE DEL PERCORSO DI SCREENING NUTRIZIONALE NELLE STRUTTURE DEL SSR E DOMICILIARE. Deliberazione XII / 1812. Approvato il 29 gennaio 2024”.
- 28. **ASPEN, ESPEN, FELANPE. 2022.** “The International Declaration on the Human Right to Nutritional Care”.
- 29. **ESPEN FACT SHEETS. s.d.** “Vienna Declaration”.
- 30. **Lionhealth.**
- 31. **Saibeni. 2023.** “Nutritional care at centres managing patients with inflammatory bowel disease: A nationwide survey in Italy”. Digestive and Liver Disease, giugno.
- 32. **Bezzio. 2024.** “Prevalence, Risk Factors and Association with Clinical Outcomes of Malnutrition and Sarcopenia in Inflammatory Bowel Disease: A Prospective Study”. Nutrients, 16, n. 23 (21 novembre): 3983.
- 33. **Cammarota. 2024.** “Review Article: Green Management of IBD—New Paradigms for an Eco‐Friendly Approach”. Alimentary Pharmacology & Therapeutics, 18 novembre.
- 34. **AMICI Italia & SINPE. s.d.** “LA MALNUTRIZIONE NELLE MALATTIE INFIAMMATORIE CRONICHE INTESTINALI (MICI): RISULTATI PRELIMINARI DELL’INDAGINE 2024 AMICI ITALIA”.
- 35. **Falcone. s.d.** “Malnutrizione e malattie infiammatorie croniche intestinali (MICI): necessità di un frame normativo nazionale per garantire equità nella presa in carico nutrizionale.”.
- 36. **Fiorindi. 2020.** “GLIM Criteria for Malnutrition in Surgical IBD Patients: A Pilot Study”. Nutrients, 12, n. 8 (25 luglio): 2222.
- 37. **Casanova. 2017.** “Prevalence of Malnutrition and Nutritional Characteristics of Patients With Inflammatory Bowel Disease”. Journal of Crohn’s and Colitis, 11, n. 12 (24 luglio): 1430–39.
- 38. **Pradelli. 2022.** “Prevalence and economic cost of malnutrition in Italy: a systematic review and metanalysis from the Italian Society of Artificial Nutrition and Metabolism (SINPE)”. Nutrition, dicembre, 111943.
- 39. **Elia. 2016.** “A systematic review of the cost and cost effectiveness of using standard oral nutritional supplements in community and care home settings”. Clinical Nutrition, 35, n. 1 (febbraio): 125–37.
- 40. **NICE. 2017.** “Nutrition support for adults: oral nutrition support, enteral tube feeding and parenteral nutrition (CG32)”. Clinical Guideline.
- 41. **Philipson. 2013.** “OP015 IMPACT OF ORAL NUTRITIONAL SUPPLEMENTATION ON HOSPITAL OUTCOMES”. Clinical Nutrition, 32 (settembre): S6—S7.
- 42. **Brennan. 2018.** “Does preoperative enteral or parenteral nutrition reduce postoperative complications in Crohn’s disease patients”. European Journal of Gastroenterology & Hepatology, 30, n. 9 (settembre): 997–1002.
- 43. **Niccolai. s.d.** “La dimensione ESG nelle gare: l’approccio green e social negli appalti pubblici. Il ruolo e l’esperienza delle centrali di committenza.”.
- 44. **Ministero della Salute. 2024.** “Integratori alimentari e Linee Guida Ministeriali (LGM)”.
- 45. **Unione Europea.** “a. Regolamento (CE) 1924/2006. Approvato il 20 dicembre 2006. Gazzetta ufficiale dell’Unione europea”.
- 46. **Ansell. 2008.** “Pharmacology and Management of the Vitamin K Antagonists”. Chest, 133, n. 6 (giugno): 160S—198S.
- 47. **Forbes. 2017.** “ESPEN guideline: Clinical nutrition in inflammatory bowel disease”. Clinical Nutrition, 36, n. 2 (aprile): 321–47.
- 48. **Barazzoni. 2022.** “Guidance for assessment of the muscle mass phenotypic criterion for the Global Leadership Initiative on Malnutrition (GLIM) diagnosis of malnutrition”. Clinical Nutrition, aprile.
- 49. **Unione Europea. 2013.** “REGOLAMENTO (UE) 609/2013. Approvato il 12 giugno 2013. Gazzetta ufficiale dell’Unione europea”.
- 50. **Unione Europea. 2015.** “REGOLAMENTO DELEGATO (UE) 2016/128. Approvato il 25 settembre 2015. Gazzetta ufficiale dell’Unione europea”.
- 51. **Ministero della Salute.** “DIREZIONE GENERALE IGIENE E SICUREZZA DEGLI ALIMENTI E NUTRIZIONE – UFFICIO 4. Revisione novembre 2018. s.d. Linee di indirizzo sugli studi condotti per valutare la sicurezza e le proprietà di prodotti alimentari”.
- 52. **Muscaritoli. 2017.** “Prevalence of malnutrition in patients at first medical oncology visit: the PreMiO study”. Oncotarget, 8, n. 45 (10 agosto): 79884–96.
- 53. **Muscaritoli. 2021.** “Linea guida pratica ESPEN: nutrizione clinica nel cancro”. SINPE.
- 54. **Pedrazzoli. 2024.** “IL SUPPORTO NUTRIZIONALE NEL PAZIENTE IN TERAPIA ATTIVA”. LINEE GUIDA AIOM.
- 55. **Elia. 2018.** “Cost-effectiveness of oral nutritional supplements in older malnourished care home residents”. Clinical Nutrition, 37, n. 2 (aprile): 651–58.
- 56. **ANAC. 2017.**
- 57. **Hatamzade Esfahani. 2023.** “The Role of TGF-β, Activin and Follistatin in Inflammatory Bowel Disease”. Gastrointestinal Disorders, 5, n. 2 (11 aprile): 167–86.
- 58. **Barberio. 2025.** “Dietary Interventions and Oral Nutritional Supplementation in Inflammatory Bowel Disease: Current Evidence and Future Directions”. Nutrients, 17, n. 11 (30 maggio): 1879.
- 59. **Fiorino. 2025.** “Adaptation of the European Crohn’s Colitis Organisation quality of care standards to Italy: The Italian Group for the study of inflammatory bowel disease consensus”. Digestive and Liver Disease, aprile.
- 60. **Italia. 2017.**
- 61. **Malnutrition-Related healthcare costs in hospitalized patients with Inflammatory Bowel Disease: a nationwide real world data analysis.**
- 62. **Oral Nutritional Supplementation Following Upper Gastrointestinal Cancer Surgery: A Prospective Analysis Exploring Potential Barriers to Compliance.**
- 63. **Questionario MUST. 2003.**
- 64. **AIOM. 2024.** “I numeri del cancro in Italia 2024”.
- 65. **Federazione UNIAMO.**
- 66. **settembre.**
- 67. **Giornata mondiale della BPCO.**
- 68. **Chen. 2025.** “The efficacy of infliximab combined with partial enteral nutrition in the treatment of Crohn’s disease”. Frontiers in Nutrition.
- 69. **WHO Europe.** “Disease-Related Malnutrition: A Time for Action”.
- 70. **Grand View Research. 2018.** “Europe Medical Foods Market Analysis, 2018–2030”.
- 71. **Deng M.** “Global prevalence of malnutrition in patients with chronic obstructive pulmonary disease: Systemic review and meta-analysis”. Clinical Nutrition.
- 72. **BAPEN.** “BAPEN MUST-toolkit”.
- 73. **Cruz-Jentoft. 2019.** “Sarcopenia: revised European consensus on definition and diagnosis”. Age and Ageing, 48, n. 1 (gennaio): 16–31.
- 74. **Osservatorio Malattie Rare. 2024.** “Malattie infiammatorie croniche intestinali in Italia: sono 250mila i pazienti”. 21 maggio.
- 75. **AMICI Italia. 2026.** “Survey AMICI Italia 2026”. Data on file, in corso di pubblicazione.
- 76. **Ministero della Salute. 2025.** “Relazione illustrativa: Primo aggiornamento del decreto del Presidente del Consiglio dei Ministri 12 gennaio 2017 in materia di livelli essenziali di assistenza”.
- 77. **Beaudart. 2017.** “Health Outcomes of Sarcopenia: A Systematic Review and Meta-Analysis”. PLoS One, 17 gennaio.
- 78. **Beaudart. 2023.** “Sarcopenia and health-related quality of life: A systematic review and meta-analysis”. Journal of Cachexia, Sarcopenia and Muscle, giugno.
- 79. **Calvez. 2024.** “Navigating the Intersection: Sarcopenia and Sarcopenic Obesity in Inflammatory Bowel Disease”. Biomedicines, 12, n. 6: 1218.
- 80. **Feng. 2024.** “Sarcopenia and treatment failure in inflammatory bowel disease: a systematic review and meta-analysis”. Revista Española de Enfermedades Digestivas, 116, n. 2 (febbraio): 68–76.
- 81. **Kuzuya. 2025.** “Nutritional Management Guidelines for Sarcopenia and Frailty 2025”. Geriatrics & Gerontology International, 25: 5–53.
- 82. **Pozzi. 2026.** “Gestione nutrizionale di un paziente con Malattia di Crohn post-resezione ileocecale e malnutrizione severa”. Nutrienti & Supplementi, febbraio.
- 83. **Arends. 2024.** “Malnutrition in cancer patients: Causes, consequences and treatment options”. European Journal of Surgical Oncology.
